24 studies found for:    Open Studies | "Acromegaly"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Acromegaly"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Prospective Study of Outcome After Therapy for Acromegaly
Condition: Acromegaly
Interventions: Procedure: Surgery for acromegaly;   Drug: Medications for acromegaly
2 Recruiting Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Condition: Acromegaly
Intervention: Drug: Pasireotide LAR
3 Recruiting Acromegaly & Sleep Apnoea
Condition: Acromegaly
Intervention:
4 Recruiting Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Condition: Acromegaly
Interventions: Drug: Octreotide capsules;   Drug: Injectable Somatostatin Analogs (octreotide or lanreotide);   Drug: Cabergoline
5 Not yet recruiting Strict IGF-1 Control in Acromegaly
Condition: Acromegaly
Intervention: Drug: Pegvisomant
6 Recruiting Late Effects of Radiosurgery on Acromegaly Study
Condition: Acromegaly
Intervention: Device: Gamma Knife radiosurgery
7 Recruiting IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly
Condition: Acromegaly
Intervention:
8 Recruiting Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation
Condition: Acromegaly
Intervention: Device: Fiberoptic
9 Recruiting Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly
Condition: Acromegaly
Interventions: Other: 1H/31P Magnetic Resonance Spectroscopy;   Other: oral glucose tolerance testing;   Other: Thyroid sonography
10 Recruiting Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Condition: Acromegaly
Intervention: Drug: Lanreotide PRF
11 Not yet recruiting Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy
Condition: Acromegaly Cardiomyopathy
Intervention: Drug: Tadalafil
12 Recruiting Acromegaly Combination Treatment Study
Condition: Acromegaly
Interventions: Drug: Pegvisomant;   Drug: Somatostatin Receptor Ligand (SRL)
13 Recruiting Cardiac (CMRI) Assessment of Acromegaly
Condition: Acromegaly
Interventions: Device: CMRI;   Drug: Gadolinium;   Procedure: OGTT
14 Recruiting Acromegaly Treatment Quality of Life Study
Condition: Acromegaly
Intervention:
15 Recruiting The Treatment and Natural History of Acromegaly
Conditions: Acromegaly;   Pituitary Neoplasm
Intervention:
16 Recruiting Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Conditions: Cushing's Disease;   Acromegaly
Interventions: Drug: Pasireotide s.c.;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin;   Drug: Pasireotide LAR;   Drug: Metformin
17 Recruiting Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
Condition: Acromegaly
Intervention:
18 Recruiting Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
Condition: Acromegaly
Intervention: Drug: Sandostatin (Octreotide Acetate)
19 Recruiting Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment
Conditions: Acromegaly;   Excessive Growth Hormone Secretion;   Insulin Resistance
Intervention: Procedure: Transsphenoidal adenomectomy
20 Recruiting Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Conditions: Acromegaly;   Gigantism;   Familial Isolated Pituitary Adenoma;   FIPA;   Pituitary Adenoma Predisposition;   PAP
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.